US 12,416,051 B2
Method of predicting survival rates for cancer patients
Robert Charles Swanton, London (GB); Dhruva Biswas, London (GB); Nicholas McGranahan, London (GB); and Nicolai Juul Birkbak, Aarhus (DK)
Assigned to The Francis Crick Institute Limited, London (GB); and University College London, London (GB)
Appl. No. 17/427,329
Filed by The Francis Crick Institute Limited, London (GB); and University College London, London (GB)
PCT Filed Jan. 30, 2020, PCT No. PCT/GB2020/050221
§ 371(c)(1), (2) Date Jul. 30, 2021,
PCT Pub. No. WO2020/157508, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 1901439 (GB), filed on Feb. 1, 2019.
Prior Publication US 2022/0136063 A1, May 5, 2022
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] 14 Claims
 
1. A method of treatment of a subject with lung cancer comprising the steps of predicting a level of risk of mortality for a subject with lung cancer the method comprising:
(a) contacting a biological sample from the subject with reagents that specifically bind to each member of a panel of biomarkers consisting of ANLN, ASPM, CDCA4, ERRFI1, FURIN, GOLGA8A, ITGA6, JAG1, LRP12, MAFF, MRPS17, PLK1, PNP, PPP1R13L, PRKCA, PTTG1, PYGB, RPP25, SCPEP1, SLC46A3, SNX7, TPBG, and XBP1;
(b) determining a risk score of the subject based on the nucleic acid levels of expression of the biomarkers in the samples;
(c) comparing the risk score to a threshold to predict whether the subject is at high or low risk of mortality;
(d) selecting a treatment from surgical treatment, chemotherapy, radiotherapy, immunotherapy or CAR-T therapy,
wherein for a subject at low risk of mortality the selected treatment is surgical treatment alone, and
wherein for a subject at high risk of mortality the selected treatment is surgical treatment, and chemotherapy, radiotherapy, immunotherapy or CAR-T therapy; and
(e) administering the treatment.